Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prognostic marker of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

ABSTRACT: Prognostic marker of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

PROVIDER: PRJNA993714 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Prognostic marker of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Project description:The data contains Illumina 450k array methylation files from 380 patients with diffuse IDH wild-type glioma from the EORTC-26101 trial

2023-07-12 | GSE237103 | GEO

Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Project description:These dataset contains NGS data from 380 samples from the EORTC-26101 clinical trial for patients with progressive glioblastoma.

| EGAS00001007421 | EGA

Different gene expression profiles between de novo and progressive muscle invasive bladder cancer: prognostic implications

Project description:INTRODUCTION: Progressive muscle-invasive bladder cancer (MIBC) has more aggressive behavior than de novo MIBC. This study aimed to ascertain the differences in gene expression profiles between both MIBC groups and to identify prognostic biomarkers to improve the treatment in these patients. MATERIAL AND METHODS: Retrospective multicentre study in which 212 MIBC patients (104 progressive and 108 de novo) who underwent radical cystectomy in the Hospital Clinic (Barcelona) and Radboud UMC (Nijmegen) were included. Total RNA from formalin-fixed paraffin-embedded tissue samples was obtained. Gene expression profiles of 27,965 coding transcripts were determined in 26 patients using Illumina microarrays. Expression levels of 94 genes selected from microarray data and literature were studied by quantitative PCR in an independent series of 186 de novo and progressive MIBC patients. Survival analysis was performed with the Kaplan-Meier method. R-software and SPSSv23 were used for all calculations. RESULTS: A total of 480 genes were found differently expressed (FDR<0.01) between progressive and de novo MIBC samples. Differential expression of 23 out of the 94 genes selected was validated in an independent set of samples. Survival analysis showed that expression of eight genes were prognostic factors of BCR. CONCLUSION: De novo and progressive MIBC patients show different gene expression profiles. In addition, we have identified eight genes with prognostic value which may contribute to improve BC risk stratification and, consequently, to tailor treatment and surveillance strategies in these patients.

2021-03-23 | GSE149582 | GEO

MicroRNA profiling by array of human sepsis patients after surgery identifies miR-150 as a plasma prognostic marker

Project description:MicroRNA fingerprints in sepsis patients after surgery identify miR-150 as a plasma prognostic marker

2009-10-27 | E-TABM-713 | biostudies-arrayexpress

Integrin αV is a prognostic marker for cutaneous squamous cell carcinoma relapse

Project description:Integrin αV is a prognostic marker for cutaneous squamous cell carcinoma relapse

| PRJNA975958 | ENA

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

Project description:DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

| PRJNA862519 | ENA

FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer

Project description:Cancer-associated fibroblasts (CAFs), although considered as the most abundant pancreatic ductal adenocarcinoma (PDAC) stromal cells playing a critical role in tumor progression and chemoresistance, are not yet directly druggable. Here we report that focal adhesion kinase (FAK) activity (evaluated based on 397 tyrosine phosphorylation level) in CAFs is highly increased compared to its activity in fibroblasts from healthy pancreas. Fibroblastic FAK activity is an independent prognostic marker for disease free and overall survival of PDAC patients (cohort of 120 PDAC samples). Genetic inactivation of FAK within fibroblasts (FAK-kinase-dead, KD) reduces fibrosis and immunosuppressive cell number within primary tumor and dramatically decreases tumor spread. Mechanistically, pharmacologic and genetic fibroblastic FAK inactivation reduces fibroblast migration/invasion, decreases extracellular matrix (ECM) expression and deposition by CAFs, and negatively impacts M2 macrophage polarization and migration. Thus, FAK activity within CAFs appears as an independent PDAC prognostic marker and a druggable driver of tumor cell invasion.

2020-08-19 | PXD018899 | Pride

Different gene expression profiles between de novo and progressive muscle invasive bladder cancer: prognostic implications

Project description:Different gene expression profiles between de novo and progressive muscle invasive bladder cancer: prognostic implications

| PRJNA629311 | ENA

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma [ChIP-seq]

Project description:DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma [ChIP-seq]

| PRJNA862523 | ENA

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma [RNA-seq]

Project description:DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma [RNA-seq]

| PRJNA862522 | ENA